INVIVO THERAPEUTICS HLDGS CO's ticker is NVIV and the CUSIP is 46186M209. A total of 65 filers reported holding INVIVO THERAPEUTICS HLDGS CO in Q3 2016. The put-call ratio across all filers is 4.12 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2017 | $140,000 | +0.7% | 34,599 | +4.6% | 0.00% | – |
| Q4 2016 | $139,000 | -47.3% | 33,090 | -14.7% | 0.00% | -100.0% |
| Q3 2016 | $264,000 | +18.4% | 38,798 | +0.8% | 0.00% | 0.0% |
| Q2 2016 | $223,000 | +26.7% | 38,498 | +52.7% | 0.00% | 0.0% |
| Q1 2016 | $176,000 | -3.3% | 25,214 | 0.0% | 0.00% | 0.0% |
| Q4 2015 | $182,000 | -8.1% | 25,214 | +10.0% | 0.00% | 0.0% |
| Q3 2015 | $198,000 | -44.1% | 22,924 | +4.6% | 0.00% | 0.0% |
| Q2 2015 | $354,000 | – | 21,915 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| IMS Capital Management | 246,966 | $1,778,000 | 2.19% |
| WELCH & FORBES LLC | 902,286 | $6,496,000 | 0.21% |
| Alambic Investment Management, L.P. | 25,100 | $181,000 | 0.11% |
| EMERSON INVESTMENT MANAGEMENT, LLC | 74,175 | $534,000 | 0.10% |
| Hayek Kallen Investment Management | 10,965 | $79,000 | 0.06% |
| Yellowstone Partners, LLC | 10,045 | $72,000 | 0.03% |
| Ausdal Financial Partners, Inc. | 7,750 | $56,000 | 0.03% |
| LANDSCAPE CAPITAL MANAGEMENT, L.L.C. | 29,647 | $213,000 | 0.03% |
| GROUP ONE TRADING, L.P. | 61,856 | $445,000 | 0.01% |
| Cambridge Investment Research Advisors, Inc. | 10,500 | $76,000 | 0.00% |